Trial · NCT07910279
Curcumin Nano Patch and Autonomic Function in Shift-Working Healthcare Professionals
NCT07910279, Not applicable, Completed, Taipei Medical University Shuang Ho Hospital
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Curcumin Nano Patch and Autonomic Function in Shift-Working Healthcare Professionals. Trials, record NCT07910279. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910279
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Curcumin Nano Patch and Autonomic Function in Shift-Working Healthcare Professionals
- NCT number
- NCT07910279
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 51 participants, actual
- Lead sponsor
- Taipei Medical University Shuang Ho Hospital
- Conditions
- Occupational Stress, Sleep Quality
- Interventions
- Curcumin Nano Patch, Cooling Control Patch (Placebo)
- First posted
- 2026-11-02
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Standard Deviation of Normal-to-Normal Intervals (SDNN) | Each of two intervention periods of at least 14 days, separated by at least 14 days of washout; approximately 7 weeks total. Additional baseline analysis uses 3 pre-intervention dates and up to 3 final washout records. | SDNN is the standard deviation of normal-to-normal intervals, expressed in milliseconds. For each participant, available SDNN recordings are averaged separately within the curcumin and cooling placebo periods. These two period means are compared as paired observations using the two-sided Wilcoxon signed-rank test. Baseline-normalized comparisons are additional analyses defined in the Detailed Description. The period-level comparison includes available recordings across each period, rather than a single resting or night-only measurement. |
| Primary | Root Mean Square of Successive Differences Between Normal-to-Normal Intervals (RMSSD) | Each of two intervention periods of at least 14 days, separated by at least 14 days of washout; approximately 7 weeks total. Additional baseline analysis uses 3 pre-intervention dates and up to 3 final washout records. | RMSSD is the root mean square of successive differences between normal-to-normal intervals, expressed in milliseconds. For each participant, available RMSSD recordings are averaged separately within the curcumin and cooling placebo periods. These two period means are compared as paired observations using the two-sided Wilcoxon signed-rank test. Baseline-normalized comparisons are additional analyses defined in the Detailed Description. The period-level comparison includes available recordings across each period. |
| Primary | Low-Frequency Power of Heart Rate Variability (LF) | Each of two intervention periods of at least 14 days, separated by at least 14 days of washout; approximately 7 weeks total. Additional baseline analysis uses 3 pre-intervention dates and up to 3 final washout records. | LF is HRV power in the 0.04-to-0.15-Hz frequency band. For each participant, available LF recordings are averaged separately within the curcumin and cooling placebo periods. These two period means are compared as paired observations using the two-sided Wilcoxon signed-rank test. Baseline-normalized comparisons are additional analyses defined in the Detailed Description. The period-level comparison includes available recordings across each period. |
| Primary | High-Frequency Power of Heart Rate Variability (HF) | Each of two intervention periods of at least 14 days, separated by at least 14 days of washout; approximately 7 weeks total. Additional baseline analysis uses 3 pre-intervention dates and up to 3 final washout records. | HF is HRV power in the 0.15-to-0.4-Hz frequency band. For each participant, available HF recordings are averaged separately within the curcumin and cooling placebo periods. These two period means are compared as paired observations using the two-sided Wilcoxon signed-rank test. Baseline-normalized comparisons are additional analyses defined in the Detailed Description. The period-level comparison includes available recordings across each period. |
| Primary | Ratio of Low-Frequency to High-Frequency Power (LF/HF) | Each of two intervention periods of at least 14 days, separated by at least 14 days of washout; approximately 7 weeks total. Additional baseline analysis uses 3 pre-intervention dates and up to 3 final washout records. | LF/HF is the dimensionless ratio of LF power (0.04-0.15 Hz) to HF power (0.15-0.4 Hz). For each participant and intervention period, LF/HF is calculated as mean LF divided by mean HF. Both means must be available and mean HF must be nonzero. The curcumin-period and cooling placebo-period ratios are compared as paired observations using the two-sided Wilcoxon signed-rank test. Baseline LF/HF uses the same ratio-of-means calculation on the selected baseline records; normalized comparisons are additional analyses defined in the Detailed Description. |
| Secondary | 10-Item Perceived Stress Scale (PSS-10) Total Score | At the beginning and end of each of the two intervention periods (4 assessments); each period lasts at least 14 days, with a washout of at least 14 days; approximately 7 weeks total. | Self-reported perceived stress is assessed using the 10-item Perceived Stress Scale (PSS-10). Each item is scored from 0 to 4. Items 4, 5, 7 and 8 are reverse-scored before the 10 item scores are summed. The total score ranges from 0 to 40, with higher scores indicating greater perceived stress (a worse outcome). Total scores and changes from the beginning to the end of each intervention period are compared within participants between the curcumin and cooling control patch conditions. |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) Global Score | At the beginning and end of each of the two intervention periods (4 assessments); each period lasts at least 14 days, with a washout of at least 14 days; approximately 7 weeks total. | Self-reported sleep quality is assessed using the Pittsburgh Sleep Quality Index (PSQI). Seven component scores, each ranging from 0 to 3, are summed to produce a global score ranging from 0 to 21. Higher global scores indicate poorer sleep quality (a worse outcome). Global scores and changes from the beginning to the end of each intervention period are compared within participants between the curcumin and cooling control patch conditions. |
| Secondary | 7-Item Generalized Anxiety Disorder (GAD-7) Total Score | At the beginning and end of each of the two intervention periods (4 assessments); each period lasts at least 14 days, with a washout of at least 14 days; approximately 7 weeks total. | Self-reported anxiety symptoms are assessed using the 7-item Generalized Anxiety Disorder (GAD-7) questionnaire. Each item is scored from 0 to 3, and the seven item scores are summed to produce a total score ranging from 0 to 21. Higher total scores indicate more severe anxiety symptoms (a worse outcome). Total scores and changes from the beginning to the end of each intervention period are compared within participants between the curcumin and cooling control patch conditions. |
| Secondary | 9-Item Patient Health Questionnaire (PHQ-9) Total Score | At the beginning and end of each of the two intervention periods (4 assessments); each period lasts at least 14 days, with a washout of at least 14 days; approximately 7 weeks total. | Self-reported depressive symptoms are assessed using the 9-item Patient Health Questionnaire (PHQ-9). Each item is scored from 0 to 3, and the nine item scores are summed to produce a total score ranging from 0 to 27. Higher total scores indicate more severe depressive symptoms (a worse outcome). Total scores and changes from the beginning to the end of each intervention period are compared within participants between the curcumin and cooling control patch conditions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910279
GET https://conductscience.org/api/trials/v1/NCT07910279/registered